Access to Medicine
Access to Medicine
Every two years, the Access to Medicine Foundation, an independent non-profit organization founded in 2005, benchmarks 20 of the world’s largest pharmaceutical companies based on their efforts to advance global access to medicines.
Our company is committed to improving sustainable access to high-quality solutions for all communities and patients in need.
We are in the TOP FIVE!
We rank 5th in the ATM Index 2022!
We rank 4th in Research & Development with our innovative pipeline, structured access planning, and capacity-building initiatives.
We rank 5th in Product Delivery driven by Intellectual Property sharing to third-party researchers in low- and middle-income countries and, high-quality capacity building initiatives across all fields – R&D, manufacturing, supply chain, health system strengthening. As part of our Global Health strategy, we are leaders in the fight against the neglected tropical disease, schistosomiasis, conducting collaborative initiatives across the health value chain.
We continue to improve our approach to equitable and sustainable access to our health solutions as we strive for our Sustainability Target to improve the health and well-being of over 1 billion people by 2030.
Facts & Figures
the low- and middle-income countries in the scope of the ATM Index 2022
the diseases in the scope of the ATM Index 2022
Access to Medicine Index 2022
The Access to Medicine Foundation benchmarks 20 of the world’s largest pharmaceutical companies across a range of indicators grouped into three areas: Governance of Access, R&D and Product Delivery.
Related NewsView all corporate news
Merck KGaA, Darmstadt, Germany, today announced that it ranks fourth in the 2018 Access to Medicine Index, maintaining its ranking among the top five since the last Index in 2016.
Merck KGaA, Darmstadt, Germany a leading science and technology company, announced today it now ranks fourth in the 2016 Access to Medicine Index, climbing two ranks since the last Index in 2014.